Compendium of Cancer Genome Aberrations

Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][unchecked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 4: Line 4:
|-
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned (Target Page Completion Date)'''!!'''Associate Editor'''
!'''Date Assigned to Author (Target Completion Date)'''!!'''Associate Editor'''
!Author Content Pending or Complete (Date Completed)
!'''Author Content Pending or Complete (Date Completed)'''
!Editor Reviewed (Date)
!'''Date Completed by Author'''
!Notes
!'''Editor Reviewed (Date of Last Review)'''
!'''Notes'''
|-
|-
|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera
|'''''Myeloproliferative Neoplasms (MPN)'''''||'''''Overview'''''||Mark Evans (trainee), Fabiola Quintero-Rivera
Line 13: Line 14:
|Fabiola Quintero-Rivera (FQR)
|Fabiola Quintero-Rivera (FQR)
|PENDING
|PENDING
|
|
|
|
|
Line 21: Line 23:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 29: Line 32:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 37: Line 41:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 45: Line 50:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 53: Line 59:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 61: Line 68:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 69: Line 77:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 74: Line 83:
|'''''Mastocytosis'''''||'''''Overview'''''||
|'''''Mastocytosis'''''||'''''Overview'''''||
| ||FQR
| ||FQR
|
|
|
|
|
Line 83: Line 93:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 91: Line 102:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 99: Line 111:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 106: Line 119:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 113: Line 127:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 120: Line 135:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 127: Line 143:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 134: Line 151:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 143: Line 161:
|FQR
|FQR
|Complete
|Complete
|
|
|
|NON-WHO ENTITY
|NON-WHO ENTITY
Line 152: Line 171:
|FQR
|FQR
|Complete
|Complete
|
|
|
|NON-WHO ENTITY
|NON-WHO ENTITY
Line 159: Line 179:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 166: Line 187:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 173: Line 195:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 180: Line 203:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 187: Line 211:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 194: Line 219:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 200: Line 226:
|
|
|FQR
|FQR
|
|
|
|
|
Line 208: Line 235:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 215: Line 243:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 222: Line 251:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 229: Line 259:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 236: Line 267:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 243: Line 275:
|FQR
|FQR
|Complete
|Complete
|
|
|
|
|
Line 250: Line 283:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 257: Line 291:
|FQR
|FQR
|PENDING
|PENDING
|
|
|
|
|
Line 262: Line 297:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 270: Line 306:
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Complete
|Complete
|
|
|
|
|
Line 276: Line 313:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 282: Line 320:
| ||JH / MS
| ||JH / MS
|PENDING
|PENDING
|
|
|
|
|
Line 288: Line 327:
| ||JH / MS
| ||JH / MS
|PENDING
|PENDING
|
|
|
|
|
Line 294: Line 334:
| ||JH / MS
| ||JH / MS
|PENDING
|PENDING
|
|
|
|
|
Line 300: Line 341:
| ||JH / MS
| ||JH / MS
|PENDING
|PENDING
|
|
|
|
|
Line 306: Line 348:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 312: Line 355:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 319: Line 363:
|JH / MS
|JH / MS
|Complete
|Complete
|
|
|
|
|
Line 325: Line 370:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 331: Line 377:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 337: Line 384:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 343: Line 391:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 349: Line 398:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 355: Line 405:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|Need permission for figure?  Update WHO?
|Need permission for figure?  Update WHO?
Line 361: Line 412:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 367: Line 419:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 373: Line 426:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|Add WHO reference
|Add WHO reference
Line 379: Line 433:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 385: Line 440:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 391: Line 447:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 397: Line 454:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|Check reference format
|Check reference format
Line 403: Line 461:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 409: Line 468:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 415: Line 475:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 421: Line 482:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 427: Line 489:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 433: Line 496:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 439: Line 503:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 445: Line 510:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 451: Line 517:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 457: Line 524:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 463: Line 531:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 469: Line 538:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|Need permission for figure?
|Need permission for figure?
Line 475: Line 545:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 481: Line 552:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 487: Line 559:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 493: Line 566:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 499: Line 573:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|Check reference format
|Check reference format
Line 505: Line 580:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 511: Line 587:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 517: Line 594:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|Check reference format
|Check reference format
Line 523: Line 601:
| ||JH / MS
| ||JH / MS
|Complete
|Complete
|
|
|
|
|
Line 529: Line 608:
| ||JH / MS
| ||JH / MS
|??
|??
|
|
|
|
|
Line 535: Line 615:
| ||JH / MS
| ||JH / MS
|??
|??
|
|
|
|
|
Line 544: Line 625:
|JH / MS
|JH / MS
|Complete
|Complete
|
|
|
|NON-WHO ENTITY
|NON-WHO ENTITY
Line 553: Line 635:
|JH / MS
|JH / MS
|PENDING
|PENDING
|
|
|
|NON-WHO ENTITY
|NON-WHO ENTITY
Line 562: Line 645:
|JH / MS
|JH / MS
|PENDING
|PENDING
|
|
|
|NON-WHO ENTITY
|NON-WHO ENTITY
Line 567: Line 651:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 573: Line 658:
|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''||
|'''''Precursor Lymphoid Neoplasms'''''||'''''Overview'''''||
| ||Yassmine Akkari (YA)
| ||Yassmine Akkari (YA)
|
|
|
|
|
Line 579: Line 665:
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||
|'''''B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic  Abnormalities'''''||'''''Overview'''''||
| ||YA
| ||YA
|
|
|
|
|
Line 585: Line 672:
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||
| ||YA
| ||YA
|
|
|
|
|
Line 593: Line 681:
|YA
|YA
|PENDING
|PENDING
|
|
|
|
|
Line 598: Line 687:
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||
| ||YA
| ||YA
|
|
|
|
|
Line 604: Line 694:
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||
| ||YA
| ||YA
|
|
|
|
|
Line 614: Line 705:
|YA
|YA
|Complete
|Complete
|
|
|
|
|
Line 619: Line 711:
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||
| ||YA
| ||YA
|
|
|
|
|
Line 625: Line 718:
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||
| ||YA
| ||YA
|
|
|
|
|
Line 633: Line 727:
|YA
|YA
|Complete
|Complete
|
|
|
|
|
Line 638: Line 733:
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||
| ||YA
| ||YA
|
|
|
|
|
Line 644: Line 740:
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||
| ||YA
| ||YA
|
|
|
|
|
Line 650: Line 747:
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||
| ||YA
| ||YA
|
|
|
|
|
Line 656: Line 754:
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||
| ||YA
| ||YA
|
|
|
|
|
Line 662: Line 761:
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||
| ||YA
| ||YA
|
|
|
|
|
Line 672: Line 772:
|YA
|YA
|PENDING
|PENDING
|
|
|
|NON-WHO ENTITY
|NON-WHO ENTITY
Line 677: Line 778:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 683: Line 785:
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
| ||Snehal Patel (SP)
| ||Snehal Patel (SP)
|
|
|
|
|
Line 691: Line 794:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 698: Line 802:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 705: Line 810:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 712: Line 818:
|SP
|SP
|Complete
|Complete
|
|
|
|Malini to review
|Malini to review
Line 719: Line 826:
|SP
|SP
|Complete
|Complete
|
|
|
|Malini to review
|Malini to review
Line 726: Line 834:
|SP
|SP
|Complete
|Complete
|
|
|
|Malini to review
|Malini to review
Line 733: Line 842:
|SP
|SP
|Complete
|Complete
|
|
|
|Malini to review
|Malini to review
Line 740: Line 850:
|SP
|SP
|Complete
|Complete
|
|
|
|Malini to review
|Malini to review
Line 747: Line 858:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 754: Line 866:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 759: Line 872:
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 765: Line 879:
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
| ||SP
| ||SP
|
|
|
|
|
Line 771: Line 886:
|    Mu Heavy Chain  Disease||Disease||
|    Mu Heavy Chain  Disease||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 777: Line 893:
|   Gamma Heavy Chain  Disease||Disease||
|   Gamma Heavy Chain  Disease||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 783: Line 900:
|    Alpha Heavy Chain  Disease||Disease||
|    Alpha Heavy Chain  Disease||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 791: Line 909:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 798: Line 917:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 805: Line 925:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 812: Line 933:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 819: Line 941:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 824: Line 947:
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
| ||SP
| ||SP
|
|
|
|
|
Line 830: Line 954:
|           Primary  Amyloidosis||Disease||
|           Primary  Amyloidosis||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 836: Line 961:
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 842: Line 968:
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
| ||SP
| ||SP
|
|
|
|
|
Line 848: Line 975:
|         POEMS Syndrome||Disease||
|         POEMS Syndrome||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 854: Line 982:
|         TEMPI Syndrome||Disease||
|         TEMPI Syndrome||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 862: Line 991:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 867: Line 997:
|Nodal Marginal Zone Lymphoma||Disease||
|Nodal Marginal Zone Lymphoma||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 875: Line 1,006:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 882: Line 1,014:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 889: Line 1,022:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 896: Line 1,030:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 903: Line 1,038:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 910: Line 1,046:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 915: Line 1,052:
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 921: Line 1,059:
|Primary Cutaneous Follicle Centre Lymphoma||Disease||
|Primary Cutaneous Follicle Centre Lymphoma||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 929: Line 1,068:
|SP
|SP
|PENDING - due 8/15/20
|PENDING - due 8/15/20
|
|
|
|
|
Line 936: Line 1,076:
|SP
|SP
|PENDING - due 8/31/20
|PENDING - due 8/31/20
|
|
|
|
|
Line 943: Line 1,084:
|SP
|SP
|PENDING - due 8/15/20
|PENDING - due 8/15/20
|
|
|
|
|
Line 948: Line 1,090:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 956: Line 1,099:
|Greg Corboy (GC)
|Greg Corboy (GC)
|PENDING
|PENDING
|
|
|
|
|
Line 961: Line 1,105:
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 967: Line 1,112:
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 973: Line 1,119:
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 979: Line 1,126:
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise  Specified (NOS)||Disease||
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise  Specified (NOS)||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 985: Line 1,133:
|EBV-Positive Mucocutaneous Ulcer||Disease||
|EBV-Positive Mucocutaneous Ulcer||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 991: Line 1,140:
|Diffuse Large B-cell Lymphoma Associated with Chronic  Inflammation||Disease||
|Diffuse Large B-cell Lymphoma Associated with Chronic  Inflammation||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 997: Line 1,147:
|    Fibrin-Associated  Diffuse Large B-cell Lymphoma||Disease||
|    Fibrin-Associated  Diffuse Large B-cell Lymphoma||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,003: Line 1,154:
|Lymphomatoid Granulomatosis||Disease||
|Lymphomatoid Granulomatosis||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,009: Line 1,161:
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,015: Line 1,168:
|Intravascular Large B-cell Lymphoma||Disease||
|Intravascular Large B-cell Lymphoma||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,021: Line 1,175:
|ALK-Positive Large B-cell Lymphoma||Disease||
|ALK-Positive Large B-cell Lymphoma||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,028: Line 1,183:
| ||GC
| ||GC
|Complete
|Complete
|
|
|
|
|
Line 1,033: Line 1,189:
|Primary Effusion Lymphoma||Disease||
|Primary Effusion Lymphoma||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,039: Line 1,196:
|'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
|'''''HHV8-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
| ||GC
| ||GC
|
|
|
|
|
Line 1,045: Line 1,203:
|   Multicentric Castleman  Disease||Disease||
|   Multicentric Castleman  Disease||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,051: Line 1,210:
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,057: Line 1,217:
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,063: Line 1,224:
|Burkitt Lymphoma||Disease||
|Burkitt Lymphoma||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,069: Line 1,231:
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,075: Line 1,238:
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
| ||GC
| ||GC
|
|
|
|
|
Line 1,081: Line 1,245:
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,087: Line 1,252:
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,093: Line 1,259:
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
| ||GC
| ||GC
|
|
|
|
|
Line 1,099: Line 1,266:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,105: Line 1,273:
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||
| ||Snehal Patel (SP)
| ||Snehal Patel (SP)
|
|
|
|
|
Line 1,112: Line 1,281:
| ||SP
| ||SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,118: Line 1,288:
| ||SP
| ||SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,124: Line 1,295:
| ||SP
| ||SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,129: Line 1,301:
|Aggressive NK-cell Leukemia||Disease||
|Aggressive NK-cell Leukemia||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,135: Line 1,308:
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of  Childhood'''''||'''''Overview'''''||
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of  Childhood'''''||'''''Overview'''''||
| ||SP
| ||SP
|
|
|
|
|
Line 1,141: Line 1,315:
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,147: Line 1,322:
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease||
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,153: Line 1,329:
|    Hydroa  Vacciniforme-Like Lymphoproliferative Disorder||Disease||
|    Hydroa  Vacciniforme-Like Lymphoproliferative Disorder||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,159: Line 1,336:
|    Severe Mosquito Bite  Allergy||Disease||
|    Severe Mosquito Bite  Allergy||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,165: Line 1,343:
|Adult T-cell Leukemia/Lymphoma||Disease||
|Adult T-cell Leukemia/Lymphoma||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,171: Line 1,350:
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||
|Extranodal NK/T-cell Lymphoma, Nasal Type||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,179: Line 1,359:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,186: Line 1,367:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,193: Line 1,375:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,200: Line 1,383:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,207: Line 1,391:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,213: Line 1,398:
| ||SP
| ||SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,218: Line 1,404:
|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||
|Subcutaneous Panniculitis-Like T-cell Lymphoma||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,224: Line 1,411:
|Mycosis Fungoides||Disease||
|Mycosis Fungoides||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,230: Line 1,418:
|Sézary Syndrome||Disease||
|Sézary Syndrome||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,236: Line 1,425:
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||
| ||SP
| ||SP
|
|
|
|
|
Line 1,242: Line 1,432:
|    Lymphomatoid  Papulosis||Disease||
|    Lymphomatoid  Papulosis||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,248: Line 1,439:
|    Primary Cutaneous  Anaplastic Large Cell Lymphoma||Disease||
|    Primary Cutaneous  Anaplastic Large Cell Lymphoma||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,254: Line 1,446:
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||
| ||SP
| ||SP
|
|
|
|
|
Line 1,260: Line 1,453:
|     Primary Cutaneous  Gamma Delta T-cell Lymphoma||Disease||
|     Primary Cutaneous  Gamma Delta T-cell Lymphoma||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,266: Line 1,460:
|     Primary Cutaneous  CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||
|     Primary Cutaneous  CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,272: Line 1,467:
|     Primary Cutaneous  Acral CD8+ T-cell Lymphoma||Disease||
|     Primary Cutaneous  Acral CD8+ T-cell Lymphoma||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,278: Line 1,474:
|     Primary Cutaneous  CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||
|     Primary Cutaneous  CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,284: Line 1,481:
|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,290: Line 1,488:
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of  T Follicular Helper Cell Origin'''''||'''''Overview'''''||
|'''''Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of  T Follicular Helper Cell Origin'''''||'''''Overview'''''||
| ||SP
| ||SP
|
|
|
|
|
Line 1,298: Line 1,497:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,305: Line 1,505:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,310: Line 1,511:
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||
| ||SP
| ||SP
|
|
|
|
|
Line 1,318: Line 1,520:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,325: Line 1,528:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,332: Line 1,536:
|SP
|SP
|PENDING
|PENDING
|
|
|
|
|
Line 1,337: Line 1,542:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,343: Line 1,549:
|'''''Hodgkin Lymphomas'''''||'''''Overview'''''||
|'''''Hodgkin Lymphomas'''''||'''''Overview'''''||
| ||Associate Editor??
| ||Associate Editor??
|
|
|
|
|
Line 1,349: Line 1,556:
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,355: Line 1,563:
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
| ||
| ||
|
|
|
|
|
Line 1,361: Line 1,570:
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,367: Line 1,577:
|    Lymphocyte-Rich  Classic Hodgkin Lymphoma||Disease||
|    Lymphocyte-Rich  Classic Hodgkin Lymphoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,373: Line 1,584:
|    Mixed Cellularity  Classic Hodgkin Lymphoma||Disease||
|    Mixed Cellularity  Classic Hodgkin Lymphoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,379: Line 1,591:
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,385: Line 1,598:
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
| ||
| ||
|
|
|
|
|
Line 1,391: Line 1,605:
|Lymphomas Associated with HIV Infection||Disease||
|Lymphomas Associated with HIV Infection||Disease||
| ||
| ||
|
|
|
|
|
Line 1,397: Line 1,612:
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
| ||
| ||
|
|
|
|
|
Line 1,403: Line 1,619:
|    Non-Destructive  Post-Transplant Lymphoproliferative Disorders||Disease||
|    Non-Destructive  Post-Transplant Lymphoproliferative Disorders||Disease||
| ||
| ||
|
|
|
|
|
Line 1,413: Line 1,630:
|
|
|PENDING
|PENDING
|
|
|
|
|
Line 1,418: Line 1,636:
|'''''    Monomorphic  Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''||
|'''''    Monomorphic  Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)'''''||'''''Overview'''''||
| ||
| ||
|
|
|
|
|
Line 1,424: Line 1,643:
|          Monomorphic  B-cell PTLD||Disease||
|          Monomorphic  B-cell PTLD||Disease||
| ||
| ||
|
|
|
|
|
Line 1,430: Line 1,650:
|          Monomorphic  T/NK-cell PTLD||Disease||
|          Monomorphic  T/NK-cell PTLD||Disease||
| ||
| ||
|
|
|
|
|
Line 1,436: Line 1,657:
|    Classical Hodgkin  Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease||
|    Classical Hodgkin  Lymphoma Post-Transplant Lymphoproliferative Disorder||Disease||
| ||
| ||
|
|
|
|
|
Line 1,442: Line 1,664:
|Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative  Disorders||Disease||
|Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative  Disorders||Disease||
| ||
| ||
|
|
|
|
|
Line 1,448: Line 1,671:
|'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''||
|'''''Histiocytic and Dendritic Cell Neoplasms'''''||'''''Overview'''''||
| ||
| ||
|
|
|
|
|
Line 1,454: Line 1,678:
|Histiocytic Sarcoma||Disease||
|Histiocytic Sarcoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,460: Line 1,685:
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
| ||
| ||
|
|
|
|
|
Line 1,466: Line 1,692:
|   Langerhans Cell  Histiocytosis||Disease||
|   Langerhans Cell  Histiocytosis||Disease||
| ||
| ||
|
|
|
|
|
Line 1,472: Line 1,699:
|   Langerhans Cell  Sarcoma||Disease||
|   Langerhans Cell  Sarcoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,478: Line 1,706:
|Indeterminate Dendritic Cell Tumour||Disease||
|Indeterminate Dendritic Cell Tumour||Disease||
| ||
| ||
|
|
|
|
|
Line 1,484: Line 1,713:
|Interdigitating Dendritic Cell Sarcoma||Disease||
|Interdigitating Dendritic Cell Sarcoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,490: Line 1,720:
|Follicular Dendritic Cell Sarcoma||Disease||
|Follicular Dendritic Cell Sarcoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,496: Line 1,727:
|    Inflammatory  Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease||
|    Inflammatory  Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,502: Line 1,734:
|Fibroblastic Reticular Cell Tumor||Disease||
|Fibroblastic Reticular Cell Tumor||Disease||
| ||
| ||
|
|
|
|
|
Line 1,508: Line 1,741:
|Disseminated Juvenile Xanthogranuloma||Disease||
|Disseminated Juvenile Xanthogranuloma||Disease||
| ||
| ||
|
|
|
|
|
Line 1,514: Line 1,748:
|Erdheim-Chester Disease||Disease||
|Erdheim-Chester Disease||Disease||
| ||
| ||
|
|
|
|
|
Line 1,520: Line 1,755:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,526: Line 1,762:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,532: Line 1,769:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,538: Line 1,776:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,544: Line 1,783:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,550: Line 1,790:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,556: Line 1,797:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,562: Line 1,804:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,568: Line 1,811:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,574: Line 1,818:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,580: Line 1,825:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,586: Line 1,832:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,592: Line 1,839:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,598: Line 1,846:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,604: Line 1,853:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,610: Line 1,860:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,616: Line 1,867:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,622: Line 1,874:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,628: Line 1,881:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Line 1,634: Line 1,888:
| || ||
| || ||
| ||
| ||
|
|
|
|
|
Retrieved from "https://test.ccga.io/index.php/Volunteer_Assignments_and_Opportunities"